Hemogenyx Pharmaceuticals PLC Result of AGM (8551D)
June 28 2019 - 7:19AM
UK Regulatory
TIDMHEMO
RNS Number : 8551D
Hemogenyx Pharmaceuticals PLC
28 June 2019
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Result of Annual General Meeting
The Annual General Meeting of Hemogenyx Pharmaceuticals plc was
held at the offices of Osborne Clarke LLP, One London Wall, London
EC2Y 5EB on Friday 28 June 2019 at 11.00 am.
Voting on all of the resolutions was conducted on a show of
hands. All resolutions were passed. The full text of each of the
resolutions is set out in the notice of the meeting, which is
available on the Company's website at
https://www.hemogenyx.com/investors/default.aspx.
The numbers of proxy votes duly lodged prior to the meeting are
set out below and will also be available on the Company's website
at https://www.hemogenyx.com/investors/default.aspx.
Proxy Votes duly lodged prior to the meeting
Ordinary Resolutions Votes for % of Votes % of Total votes Total Votes
votes Against votes cast votes withheld
cast cast cast as
for against % of ISC(1)
------------ ------- --------- --------- ------------ ------------- ----------
To approve the
Company's annual
accounts for the
financial year
ended 31 December
2018 119,390,068 100% 0 N/A 119,390,068 33.1% 0
------------ ------- --------- --------- ------------ ------------- ----------
To approve the
directors' remuneration
report contained
within the annual
report and accounts
for the financial
year ended 31
December 2018 119,386,946 100% 0 N/A 119,386,946 33.1% 3,122
------------ ------- --------- --------- ------------ ------------- ----------
To re-appoint
PKF Littlejohn
LLP as auditor
of the Company 119,261,281 100% 0 N/A 119,261,281 33.1% 128,787
------------ ------- --------- --------- ------------ ------------- ----------
To authorise the
directors to determine
the level of the
auditor's remuneration 119,386,946 100% 0 N/A 119,386,946 33.1% 3,122
------------ ------- --------- --------- ------------ ------------- ----------
To provide the
directors with
authority to allot
ordinary shares 119,386,946 100% 0 N/A 119,386,946 33.1% 3,122
------------ ------- --------- --------- ------------ ------------- ----------
Special Resolutions Votes for % of Votes % of Total votes Total Votes
votes against votes cast votes withheld
cast cast cast as
for against % of ISC(1)
------------ ------- --------- --------- ------------ ------------- ----------
To disapply statutory
pre-emption rights 119,258,159 100% 0 N/A 119,258,159 33.1% 131,909
------------ ------- --------- --------- ------------ ------------- ----------
(1) The Company's issued share capital (ISC) on 28 May 2019,
being the date on which members had to be entered in the register
of members of the Company in order to be entitled to attend and
vote at the meeting, was 360,176,186 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote
in law and is not counted in the calculation of the proportion of
the votes for and against it.
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Sir Marc Feldmann, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre, Soltan
Tagiev
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded
company (LSE: HEMO) headquartered in London, with its wholly-owned
US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located
in New York City at its state-of-the-art research facility and a
wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL,
located in Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGSEIFFAFUSEFM
(END) Dow Jones Newswires
June 28, 2019 07:19 ET (11:19 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2023 to Apr 2024
